

YOU ARE CORDIALLY INVITED TO ATTEND

## A Peer-to-Peer Program

# COSENTYX® (secukinumab): A Comprehensive Approach to Treating Moderate to Severe Plaque Psoriasis



This program will feature a dermatology medical expert who will present clinical data on COSENTYX for adult patients with moderate to severe plaque psoriasis (PsO), including in difficult-to-treat regions of the body.

### PROGRAM OBJECTIVES

- Discuss efficacy and safety in moderate to severe PsO and active psoriatic arthritis (PsA)
- Highlight data showing sustained response rates and consistent safety through 4 years in PsO
- Analyze evidence from *dedicated studies* in difficult-to-treat patients
  - Scalp PsO
  - Nail PsO
  - Palmoplantar PsO

### INTENDED AUDIENCE

The intended audience for this program is health care professionals involved in the treatment of adult patients suffering from:

- Moderate to severe plaque PsO, including:
  - Nail PsO
  - Scalp PsO
  - Palmoplantar PsO
- Active PsA

**Friday, April 27, 2018**

**6:15 PM-8:15 PM EST**

### PROGRAM LOCATION

**Big Rock Chop House**  
245 South Eton Street  
Birmingham, MI 48009  
(248) 647-7774  
**Cory Rubin MD**

Dermatologist

Advanced Dermatology and Cosmetic Surgery, Beaumont Health System, St John Providence Health System

### RSVP

On behalf of Novartis Pharmaceuticals Corporation, RSVP by

**April 24, 2018**

**Bradley Lathrop**

Novartis Representative Program Host

[brad.lathrop@novartis.com](mailto:brad.lathrop@novartis.com)

(248) 914-4008

Novartis acts in accordance with the PhRMA Code on Interactions with Health Care Professionals. The PhRMA Code states that inclusion of a health care professional's spouse or guest at an educational program is not appropriate. Your support of these ethical guidelines will help to ensure a high quality learning environment for all participating health care professionals. Thank you.

### BY INVITATION ONLY

### INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis.

### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients.

Please see additional Important Safety Information on next page.

Please see accompanying full Prescribing Information, including Medication Guide.

## **IMPORTANT SAFETY INFORMATION (cont)**

### **WARNINGS AND PRECAUTIONS**

#### **Infections**

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in subjects treated with COSENTYX compared to placebo-treated subjects. In placebo-controlled clinical trials in patients with moderate to severe plaque psoriasis, higher rates of common infections such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%), and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. A similar increase in risk of infection was seen in placebo-controlled trials in patients with psoriatic arthritis. The incidence of some types of infections appeared to be dose-dependent in clinical studies.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and COSENTYX should be discontinued until the infection resolves.

#### **Pre-treatment Evaluation for Tuberculosis**

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Do not administer COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving COSENTYX should be monitored closely for signs and symptoms of active TB during and after treatment.

#### **Inflammatory Bowel Disease**

Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in patients treated with COSENTYX during clinical trials in plaque psoriasis and psoriatic arthritis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In an exploratory study in 59 patients with active Crohn's disease, there were trends toward greater disease activity and increased adverse events in the secukinumab group as compared to the placebo group. Patients who are treated with COSENTYX should be monitored for signs and symptoms of inflammatory bowel disease.

#### **Hypersensitivity Reactions**

Anaphylaxis and cases of urticaria occurred in patients treated with COSENTYX in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable cap of the COSENTYX Sensoready® pen and the COSENTYX prefilled syringe contains natural rubber latex which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

#### **Vaccinations**

Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. Patients treated with COSENTYX should not receive live vaccines.

Non-live vaccinations received during a course of COSENTYX may not elicit an immune response sufficient to prevent disease.

### **MOST COMMON ADVERSE REACTIONS**

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

**Please see additional Important Safety Information on front page.**

**Please see accompanying full Prescribing Information, including Medication Guide.**

